Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 182 | 40% |
| 2020 | 0 | 141 | 43% |
| 2021 | 0 | 124 | 48% |
| 2022 | 0 | 136 | 51% |
| 2023 | 1 | 132 | 55% |
| 2024 | 0 | 137 | 57% |
| 2025 from claims | – | 165 133–194 | 58% |
| 2026 forecast | – | 168 132–211 | 58% |
| 2027 forecast | – | 171 127–226 | 59% |
| 2028 forecast | – | 174 123–240 | 60% |
| 2029 forecast | – | 177 120–253 | 60% |
| 2030 forecast | – | 180 118–267 | 61% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 5 | 266−5.3%/yr | −5.3%/yr | 0.2 | 0% | 270 in 2030+0.2%/yr |
| Illinois | 1 | 244−3.5%/yr | −3.5%/yr | 0.2 | 0% | 310 in 2030+4.3%/yr |
| Minnesota | 3 | 172+4.2%/yr | +4.2%/yr | 0.4 | 0% | 340 in 2030+12%/yr |
| Michigan | 0 | 130−12%/yr | −12%/yr | 0.2 | 0% | 290 in 2030+14%/yr |
| Wisconsin | 0 | 105+1.8%/yr | +1.8%/yr | 0.2 | 0% | 120 in 2030+2.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 12 | 310+5.1%/yr | +5.1%/yr | 0.51.3× | 0% | 380 in 2030+3.2%/yr |
| Aneurysm & intracranial embolization | 6 | 309+17%/yr | +17%/yr | 0.51.2× | 0% | 370 in 2030+2.8%/yr |
| DBS & VNS | 3 | 276−9.1%/yr | −9.1%/yr | 0.41.3× | 0% | 290 in 2030+0.5%/yr |
CSF shunts in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Ohio
Neurolutions leads with 87% of company spending on these surgeons in 2025, +87 pts on 2024.
In 2025, 5 companies reported engagement with Missouri’s surgeons worth $75K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.